Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | NAT1 | P18440 | 3/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1871294 | 0.79 | IMPDH2 (0.36) | IMPDH2GPR84NAT1ALDH1A1CYP1A2 | |
| SCHEMBL307822 | 0.79 | ALDH1A1 (0.40) | ALDH1A1HSD17B10KMT2A | |
| SCHEMBL7772167 | 0.74 | ALDH1A1 (0.39) | ALDH1A1HSD17B10KMT2ACNR2 | |
| SCHEMBL612842 | 0.73 | ALDH1A1 (0.40) | IMPDH2ALDH1A1HSD17B10KMT2ACDK8 | |
| SCHEMBL1871297 | 0.73 | IMPDH2 (0.36) | IMPDH2GPR84NAT1CETPALDH1A1 | |
| SCHEMBL613241 | 0.72 | TPH1 (0.37) | CETPALDH1A1HSD17B10MEN1USP2 | |
| SCHEMBL612738 | 0.72 | PDK2 (0.46) | ADRA1DADRA1A | |
| SCHEMBL613025 | 0.71 | NPBWR1 (0.38) | CETPERN1 | |
| SCHEMBL613397 | 0.71 | PDK2 (0.43) | GPR84CYP3A4CYP2C19ADRA1DADRA1A | |
| SCHEMBL307807 | 0.70 | PDK2 (0.46) | ALDH1A1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808740-A1 | ORAL DOSAGE FORMS COMPRISING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | TerSera Therapeutics LLC (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3176159-B1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-2091940-B3 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3176159-A1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2589600-B1 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2091940-B1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | disclosed |
| US-8772482-B2 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2589600-A1 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2533778-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | Lexicon Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7968559-B2 | Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2011056916-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20100311764-A1 | Methods of using 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds | TERSERA THERAPEUTICS LLC | 2010-12-09 | — | — | US | disclosed |
| WO-2010065333-A1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS | LEXICON PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-7709493-B2 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090286817-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | TERSERA THERAPEUTICS LLC | 2009-11-19 | — | — | US | disclosed |
| EP-2091940-A2 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7553840-B2 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | LEXICON PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20080153852-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | TERSERA THERAPEUTICS LLC | 2008-06-26 | — | — | US | disclosed |
| WO-2008073933-A2 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286817-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | TPH1, TPH2, PAH | IMPDH2 1311/4885GPR84 1233/4885NAT1 6/4885 |
| US-20080153852-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | TPH1, TPH2, MAOA | IMPDH2 715/4885GPR84 1451/4885NAT1 20/4885 |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | TPH1, TPH2, IDO1 | IMPDH2 375/4885GPR84 931/4885NAT1 29/4885 |
| US-20100311764-A1 | Methods of using 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds | TPMT, PYGL, DPYD | IMPDH2 948/4885GPR84 4635/4885NAT1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.